Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Krozer-Makshi is a branded generic formulation of azithromycin, a macrolide antibiotic marketed by Makshi Healthcare. Azithromycin is a broad-spectrum antimicrobial agent that functions by binding to the 50S subunit of the bacterial ribosome, specifically the 23S rRNA, which inhibits the translocation step of protein synthesis and halts bacterial growth. It is widely utilized for the treatment of community-acquired respiratory infections, skin and skin structure infections, and certain sexually transmitted infections such as chlamydia. Krozer-Makshi is typically administered orally and is valued for its high intracellular concentration and prolonged tissue half-life, which allows for convenient once-daily dosing and short treatment durations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Krozer-Makshi.